Latest Breaking News On - Allogene allo - Page 4 : comparemela.com

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation. | June 3, 2023

United statesAllogene alloMadeleine goldsteinZachary robertsChristine cassianoAmerican society of clinical oncologyEuropean hematology associationCorporate pipeline communicationsAllogene therapeutics incResearch developmentDrug administrationGlobenewswire incLong term follow up dataDemonstrate potentialGenerate durable complete responses similarApproved autologous

Allogene Therapeutics Presents Updated ALLO-501/501A Phase

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to.

United statesMadeleine goldsteinAllogene alloZachary robertsChristine cassianoEuropean hematology associationResearch developmentCongress onAllogene therapeutics incAmerican society of clinical oncologyCorporate pipeline communicationsDrug administrationLong term follow up dataDemonstrate potentialGenerate durable complete responses similarApproved autologous

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 Allogene Therapeutics,. | May 11, 2023

United statesChristine cassianoAllogene alloJavier munozAmerican society of clinical oncologyCongress onLymphoma program at mayo clinicEuropean hematology associationDrug administrationAllogene therapeutics incData will also be presentedPoster sessionAmerican societyClinical oncologyAnnual meetingHybrid congress

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristine cassianoTimothy mooreDavid changAllogene alloAmerican association of cancer researchAllogene therapeutics incAllocart programAmerican association for cancer researchAmerican society of clinical oncologyDrug administrationFirst potentially pivotal phaseRefractory largeb cellSupport licensureLymphodepleting agentAmerican society

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure. | May 3, 2023

United statesDavid changChristine cassianoAllogene alloTimothy mooreAmerican association of cancer researchDrug administrationAmerican association for cancer researchAllocart programAllogene therapeutics incAmerican society of clinical oncologyEnrollment ongoingFirst potentially pivotal phaseRefractory largeb cellSupport licensureLymphodepleting agent